Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  

Khaled Musallam

Khaled Musallam: The Evolving Landscape of β-Thalassemia: Clinical Trial Advances Since 2021
Aug 13, 2026, 11:05 | Voices
Khaled Musallam: The Evolving Landscape of β-Thalassemia: Clinical Trial Advances Since 2021
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn about a…
Khaled Musallam: Caring for Women with Thalassemia From Puberty to Pregnancy and Beyond
Jul 3, 2026, 22:47 | Science
Khaled Musallam: Caring for Women with Thalassemia From Puberty to Pregnancy and Beyond
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn about a…
Khaled Musallam: Listening to Patients’ Needs and Challenges Remains the Foundation for a Better Care
May 9, 2026, 13:50 | Voices
Khaled Musallam: Listening to Patients’ Needs and Challenges Remains the Foundation for a Better Care
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn: ''One…
Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
May 6, 2026, 02:23 | Voices
Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn: "When the…
Khaled Musallam: Revisiting Global Anemia Burden with Revised WHO Hemoglobin Criteria
Apr 4, 2026, 16:09 | Voices
Khaled Musallam: Revisiting Global Anemia Burden with Revised WHO Hemoglobin Criteria
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on Linkedin about…
Khaled Musallam: UAE Approves Pyrukynd for Both Alpha and Beta Thalassemia
Mar 2, 2026, 15:56 | Drugs
Khaled Musallam: UAE Approves Pyrukynd for Both Alpha and Beta Thalassemia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn: ''Some welcome and…
Khaled Musallam on Management of Transfusion-Dependent β-Thalassaemia in LMICs
Jan 19, 2026, 15:57 | Science
Khaled Musallam on Management of Transfusion-Dependent β-Thalassaemia in LMICs
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn: ''On the first…
Khaled Musallam Applauds Hatoon Ezzat's Leadership and Healthcare Advances in Saudi Arabia
Dec 15, 2025, 15:58 | Voices
Khaled Musallam Applauds Hatoon Ezzat's Leadership and Healthcare Advances in Saudi Arabia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, reposted from Thalassaemia International Federation (TIF)…
Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
Dec 6, 2025, 11:13 | Insight
Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on reposted from The Lancet…
Khaled Musallam Takes on The Role as Chief of Cell/Gene Therapies and Hematology at Burjeel Cancer Institute
Nov 20, 2025, 16:47 | Insight
Khaled Musallam Takes on The Role as Chief of Cell/Gene Therapies and Hematology at Burjeel Cancer Institute
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn: ''Priviliged to be…
Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
Oct 27, 2025, 18:42 | Science
Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn: ''Pleased to share…
Khaled Musallam: Honored to Be Featured for The 7th Year in A Row in The World’s Top 2% Most-Cited Scientists
Oct 11, 2025, 08:11 | Voices
Khaled Musallam: Honored to Be Featured for The 7th Year in A Row in The World’s Top 2% Most-Cited Scientists
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn: ''Honored to be…
Khaled Musallam Explores Molecular Understanding of β-Thalassemia at The 2nd Abu Dhabi Hematology Annual Review
Sep 28, 2025, 08:41 | Insight
Khaled Musallam Explores Molecular Understanding of β-Thalassemia at The 2nd Abu Dhabi Hematology Annual Review
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn: ''Great program and…
Khaled Musallam: No Better Conclusion For a Clinical Trial than For It to Be Published in the LANCET
Jun 20, 2025, 17:01 | Voices
Khaled Musallam: No Better Conclusion For a Clinical Trial than For It to Be Published in the LANCET
Khaled Musallam, Director of Thalassemia & Sickle Cell Center at Burjeel Medical City, shared a…
All: 14 Posts: 1 - 100
NewsFeed